

Financial news for MGNX dated on 2020-06-05: Why MacroGenics Is Moving Today

Financial news for MGNX dated on 2020-06-05: MacroGenics shares are trading higher after the company announced the FDA has granted Orphan Drug Designation to Margetuximab in the US for gastric cancer.

Financial news for MGNX dated on 2020-06-05: MacroGenics Announces Margetuximab Granted Orphan Drug Designation In The US For Gastric Cancer

Financial news for MGNX dated on 2020-06-03: MacroGenics Highlights Publication In Science Translational Medicine Supporting Flotetuzumab Pivotal Study In Patients With Refractory Acute Myeloid Leukemia

Financial news for MGNX dated on 2020-06-01: Benzinga's Top Upgrades, Downgrades For June 1, 2020

Financial news for MGNX dated on 2020-06-01: MacroGenics shares are trading higher after Guggenheim upgraded the company's stock from Neutral to Buy.

Financial news for MGNX dated on 2020-06-01: Guggenheim Upgrades MacroGenics to Buy

Financial news for MGNX dated on 2020-06-01: 72 Biggest Movers From Friday

Financial news for MGNX dated on 2020-05-29: SVB Leerink Maintains Outperform on MacroGenics, Raises Price Target to \$27

Financial news for MGNX dated on 2020-05-29: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for MGNX dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimimmune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for MGNX dated on 2020-05-28: BTIG Maintains Buy on MacroGenics, Raises Price Target to \$35

Financial news for MGNX dated on 2020-05-28: MacroGenics Provides Update On FDA Review Of Margetuximab For HER2-Positive Metastatic Breast Cancer; Says Advisory Committee Meeting Not Required, PDUFA Goal Date Unchanged

Financial news for MGNX dated on 2020-05-28: MacroGenics Offers Update On FDA Review Of Margetuximab: Says AdCom Meeting Not Required, PDUFA Goal Date Unchanged

Financial news for MGNX dated on 2020-05-27: MacroGenics Announces Registration Study Of Flotetuzumab In Patients With Refractory Acute Myeloid Leukemia

Financial news for MGNX dated on 2020-05-26: MacroGenics shares are trading higher after HC Wainwright maintained its Buy rating on the stock and raised its price target from \$22 to \$40 per share.

Financial news for MGNX dated on 2020-05-26: HC Wainwright & Co. Maintains Buy on MacroGenics, Raises Price Target to \$40

Financial news for MGNX dated on 2020-05-24: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for MGNX dated on 2020-05-15: 60 Biggest Movers From Yesterday

Financial news for MGNX dated on 2020-05-14: 5 ASCO Abstracts Moving Biopharma Stocks

Financial news for MGNX dated on 2020-05-14: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for MGNX dated on 2020-05-14: Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.

Financial news for MGNX dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for MGNX dated on 2020-05-14: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for MGNX dated on 2020-05-14: 32 Stocks Moving in Thursday's Pre-Market Session

Financial news for MGNX dated on 2020-05-13: MacroGenics To Present Prelim. Clinical Results From MGD013, MGC018 At ASCO May 29-31

Financial news for MGNX dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for MGNX dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MGNX dated on 2020-05-12: Credit Suisse Maintains Outperform on MacroGenics, Raises Price Target to \$30

Financial news for MGNX dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for MGNX dated on 2020-05-12: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MGNX dated on 2020-05-12: 32 Stocks Moving in Tuesday's Pre-Market Session

Financial news for MGNX dated on 2020-05-12: 78 Biggest Movers From Yesterday

Financial news for MGNX dated on 2020-05-08: 84 Biggest Movers From Yesterday

Financial news for MGNX dated on 2020-05-07: Mid-Morning Market Update: Markets Open Higher; Bristol-Myers Squibb Tops Q1 Estimates

Financial news for MGNX dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for MGNX dated on 2020-05-07: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for MGNX dated on 2020-05-07: 66 Biggest Movers From Yesterday

Financial news for MGNX dated on 2020-05-06: Mid-Afternoon Market Update: NASDAQ Jumps Over 100 Points; Nautilus Shares Plummet

Financial news for MGNX dated on 2020-05-06: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MGNX dated on 2020-05-06: MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 Update

Financial news for MGNX dated on 2020-05-06: Mid-Day Market Update: Crude Oil Down 6%; Cars.com Shares Jump On Upbeat Q1 Results

Financial news for MGNX dated on 2020-05-06: Mid-Morning Market Update: Markets Mixed; General Motors Beats Q1 Views

Financial news for MGNX dated on 2020-05-06: MacroGenics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for MGNX dated on 2020-05-06: Credit Suisse Maintains Outperform on MacroGenics, Lowers Price Target to \$13

Financial news for MGNX dated on 2020-05-06: HC Wainwright & Co. Reiterates Buy on MacroGenics, Raises Price Target to \$22

Financial news for MGNX dated on 2020-05-06: SVB Leerink Reiterates Outperform on MacroGenics, Lowers Price Target to \$15

Financial news for MGNX dated on 2020-05-05: MacroGenics Q1 EPS \$(0.910) Beats \$(1.020) Estimate, Sales \$13.682M Beat \$9.540M Estimate

Financial news for MGNX dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for MGNX dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for MGNX dated on 2020-04-27: MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting

Financial news for MGNX dated on 2020-04-20: 95 Biggest Movers From Friday

Financial news for MGNX dated on 2020-04-14: 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MGNX dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for MGNX dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for MGNX dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for MGNX dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for MGNX dated on 2020-03-05: The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Financial news for MGNX dated on 2020-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2020

Financial news for MGNX dated on 2020-03-04: Barclays Initiates Coverage On MacroGenics with Underweight Rating, Announces \$8 Price Target

Financial news for MGNX dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for MGNX dated on 2020-02-28: 140 Biggest Movers From Yesterday

Financial news for MGNX dated on 2020-02-27: 95 Biggest Movers From Yesterday

Financial news for MGNX dated on 2020-02-26: Stifel Maintains Buy on MacroGenics, Lowers Price Target to \$20

Financial news for MGNX dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for MGNX dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for MGNX dated on 2020-01-21: Wedbush Maintains Outperform on MacroGenics, Raises Price Target to \$16

Financial news for MGNX dated on 2020-01-09: MacroGenics Estimated Cash, Cash Equivalents And Marketable Securities Balance As Of Dec 31, 2019 Was About \$215M

Financial news for MGNX dated on 2020-01-09: MacroGenics Outlines Corporate Priorities For 2020; Will Discontinue MGD009 And MGD007 Programs

Financial news for MGNX dated on 2019-12-23: MacroGenics Files For \$250M Mixed Shelf Offering

Financial news for MGNX dated on 2019-12-20: 28 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for MGNX dated on 2019-12-19: MacroGenics Announces Submission Of Margetuximab Biologics License Application To US FDA

Financial news for MGNX dated on 2019-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2019

Financial news for MGNX dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for MGNX dated on 2019-12-19: Cantor Fitzgerald Initiates Coverage On MacroGenics with Overweight Rating, Announces \$17 Price Target

Financial news for MGNX dated on 2019-12-17: 8 Biotech Stocks Morgan Stanley Recommends For 2020

Financial news for MGNX dated on 2019-12-11: MacroGenics Shares Resume Trade, Rebound Sharply From Low, Now Positive; Stock Up 3% For Session

Financial news for MGNX dated on 2019-12-11: MacroGenics Shares Resume Trade, Continue Lower, Now Down 14% For Session

Financial news for MGNX dated on 2019-12-11: MacroGenics Shares To Resume Trade At 10:11:48 a.m. EST

Financial news for MGNX dated on 2019-12-11: MacroGenics Shares Resume Trade, Fall To Session Low, Now Down 10.7% For Session, Immediately Halted On Second Circuit Breaker

Financial news for MGNX dated on 2019-12-11: MacroGenics Highlights Presentation Of Results From SOPHIA Study Of Margetuximab In Patients With HER2-Positive Metastatic Breast Cancer At San Antonio Breast Cancer Symposium

Financial news for MGNX dated on 2019-12-11: MacroGenics Shares Halted On Circuit Breaker

Financial news for MGNX dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for MGNX dated on 2019-12-09: MacroGenics Highlights Presentation Of Floteztuzumab Data At ASH

Financial news for MGNX dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for MGNX dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for MGNX dated on 2019-11-21: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for MGNX dated on 2019-11-21: UPDATE: Morgan Stanley On MacroGenics Notes 'Despite positive trends, we see F-allele data as unlikely to be on label. MGNX has a broad pipeline but we need to see more data before gaining confidence'

Financial news for MGNX dated on 2019-11-21: UPDATE: Morgan Stanley Downgrades MacroGenics To Underweight, Lowers Tgt From \$17 To \$6 Notes 'Margetuximab is expected to be approved but with limited market opportunity in 4L+ patients'

Financial news for MGNX dated on 2019-11-21: Stocks That Hit 52-Week Lows On Thursday

Financial news for MGNX dated on 2019-11-21: Benzinga's Top Upgrades, Downgrades For November 21, 2019

Financial news for MGNX dated on 2019-11-21: MacroGenics shares are trading lower after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and announced a price target of \$6 per share.

Financial news for MGNX dated on 2019-11-21: Morgan Stanley Downgrades MacroGenics to Underweight, Announces \$6 Price Target

Financial news for MGNX dated on 2019-11-20: Guggenheim Assumes MacroGenics at Neutral

Financial news for MGNX dated on 2019-11-11: Stocks That Hit 52-Week Lows On Monday

Financial news for MGNX dated on 2019-11-07: Stifel Nicolaus Maintains Buy on MacroGenics, Lowers Price Target to \$21

Financial news for MGNX dated on 2019-11-07: Citi Maintains Buy on MacroGenics, Lowers Price Target to \$18

Financial news for MGNX dated on 2019-11-06: MacroGenics Q3 EPS \$(0.91) Beats \$(0.98) Estimate, Sales \$18.741M Miss \$19.12M Estimate

Financial news for MGNX dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for MGNX dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for MGNX dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for MGNX dated on 2019-10-30: Stocks That Hit 52-Week Lows On Wednesday

Financial news for MGNX dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for MGNX dated on 2019-10-29: Stocks That Hit 52-Week Lows On Tuesday

Financial news for MGNX dated on 2019-10-25: Stocks That Hit 52-Week Lows On Friday

Financial news for MGNX dated on 2019-10-25: Zai Lab Highlights Partner MacroGenics Initiated Phase 2/3 Trial Of Margetuximab

Financial news for MGNX dated on 2019-10-25: MacroGenics Announces Initiation Of Phase 2/3 MAHOGANY Study Of Margetuximab In Gastric Or Gastroesophageal Junction Cancer.

Financial news for MGNX dated on 2019-10-25: The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

Financial news for MGNX dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for MGNX dated on 2019-10-24: 41 Biggest Movers From Yesterday

Financial news for MGNX dated on 2019-10-23: 26 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MGNX dated on 2019-10-23: Stocks That Hit 52-Week Lows On Wednesday

Financial news for MGNX dated on 2019-10-23: 14 Stocks Moving in Wednesday's Pre-Market Session

Financial news for MGNX dated on 2019-10-23: The Daily Biotech Pulse: Eli Lilly Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

Financial news for MGNX dated on 2019-10-23: Wedbush Maintains Outperform on MacroGenics, Lowers Price Target to \$14

Financial news for MGNX dated on 2019-10-22: MacroGenics Announces Second Interim Overall Survival Data From Phase 3 SOPHIA Study Of Margetuximab In Patients With HER2-Positive Metastatic Breast Cancer

Financial news for MGNX dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for MGNX dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for MGNX dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for MGNX dated on 2019-07-17: MacroGenics To Terminate Collaboration Agreement With Laboratoires Servier, Co. To Regain Full Global Rights To Develop And Commercialize Flotetuzumab

Financial news for MGNX dated on 2019-07-11: The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug

Financial news for MGNX dated on 2019-07-10: MacroGenics And I-Mab Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Enoblituzumab In Greater China

Financial news for MGNX dated on 2019-06-05: 54 Biggest Movers From Yesterday

Financial news for MGNX dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for MGNX dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for MGNX dated on 2019-05-31: Najarian on CNBC he is long MacroGenics and into ASCO Conference

Financial news for MGNX dated on 2019-05-17: 63 Biggest Movers From Yesterday

Financial news for MGNX dated on 2019-05-16: 5 ASCO Abstracts That Moved Stocks

Financial news for MGNX dated on 2019-05-16: Mid-Afternoon Market Update: KEMET Jumps On Upbeat Q4 Results; EDAP Shares Plunge

Financial news for MGNX dated on 2019-05-16: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for MGNX dated on 2019-05-16: Mid-Day Market Update: Crude Oil Up Over

2%; Virtusa Shares Drop Following Downbeat Q4 Earnings

Financial news for MGNX dated on 2019-05-16: MacroGenics shares are trading higher after the company reported its SOPHIA Study met its primary endpoint.

Financial news for MGNX dated on 2019-05-16: The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

Financial news for MGNX dated on 2019-05-15: MacroGenetics shares are trading higher after the company reported SOPHIA study met its primary endpoint.

Financial news for MGNX dated on 2019-05-15: UPDATE: MacroGenics Says SOPHIA Study Met Primary Endpoint

Financial news for MGNX dated on 2019-05-15: MacroGenics Reports Results From Phase 3 SOPHIA Study Of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

Financial news for MGNX dated on 2019-05-15: MacroGenics Option Alert: Jun 21 \$20 Calls at the Ask: 2416 @ \$1.15 vs 221 OI; Ref=\$15.74

Financial news for MGNX dated on 2019-05-03: UPDATE: Wedbush Upgrades MacroGenics To Outperform As Firm Believes 'current share price levels provide upside, given potential positive catalysts ahead with updated SOPHIA data at ASCO, and the possibility of a partnership agreement for margetuximab'

Financial news for MGNX dated on 2019-05-03: MacroGenics shares are trading higher due to Wedbush upgrading the company from Neutral to Outperform.

Financial news for MGNX dated on 2019-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2019

Financial news for MGNX dated on 2019-05-03: Wedbush Upgrades MacroGenics, Inc. - Common Stock to Outperform, Announces \$26 Price Target

Financial news for MGNX dated on 2019-05-01: MacroGenics Q1 EPS \$(0.99) Misses \$(0.86) Estimate, Sales \$9.7M Miss \$18.8M Estimate; Announces Oral Presentation Of Sophia Data At ASCO, Plans To Submit BLA In 2H2019

Financial news for MGNX dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for MGNX dated on 2019-04-17: Credit Suisse Initiates Coverage On MacroGenics with Outperform Rating, Announces \$29 Price Target

Financial news for MGNX dated on 2019-04-12: Guggenheim Initiates Coverage On MacroGenics with Neutral Rating

Financial news for MGNX dated on 2019-04-03: MacroGenics Highlights Presentation Of Data At The AACR Annual Meeting 2019

Financial news for MGNX dated on 2019-02-26: MacroGenics Q4 EPS \$(1.06) Misses \$(1.02) Estimate, Sales \$15.794M Beat \$10.67M Estimate

Financial news for MGNX dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for MGNX dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for MGNX dated on 2019-02-13: The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Financial news for MGNX dated on 2019-02-12: MacroGenics Prices 5.5M Share Public Offering of Common Stock @\$20/Share

Financial news for MGNX dated on 2019-02-12: MacroGenics Reports Common Stock Offering; Size Not Disclosed

Financial news for MGNX dated on 2019-02-08: 72 Biggest Movers From Yesterday

Financial news for MGNX dated on 2019-02-07: 8 Biggest Price Target Changes For Thursday

Financial news for MGNX dated on 2019-02-07: Benzinga's Top Upgrades, Downgrades For February 7, 2019

Financial news for MGNX dated on 2019-02-07: UPDATE: Wedbush Downgrades MacroGenics To Neutral And Raises Price Target From \$20 To \$26 As Firm Awaits 'the presentation of a more detailed dataset at a medical meeting later this half, particularly

regarding PFS duration'

Financial news for MGNX dated on 2019-02-07: Wedbush Downgrades MacroGenics to Neutral

Financial news for MGNX dated on 2019-02-07: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for MGNX dated on 2019-02-07: The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alektor To Debut

Financial news for MGNX dated on 2019-02-07: Raymond James Upgrades MacroGenics to Market Perform

Financial news for MGNX dated on 2019-02-07: Citigroup Upgrades MacroGenics to Buy, Raises Price Target to \$39

Financial news for MGNX dated on 2019-02-07: 62 Biggest Movers From Yesterday

Financial news for MGNX dated on 2019-02-06: Mid-Afternoon Market Update: Container Store Drops On Earnings Miss; MacroGenics Shares Climb

Financial news for MGNX dated on 2019-02-06: Hearing Raymond James Upgraded MacroGenics From Underperform To Market Perform; Unconfirmed

Financial news for MGNX dated on 2019-02-06: MacroGenics Option Alert: Jul 19 \$30 Calls Sweep (2) near the Bid: 1857 @ \$3.3 vs 24 OI; Earnings 2/26 After Close [est] Ref=\$25.095

Financial news for MGNX dated on 2019-02-06: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MGNX dated on 2019-02-06: Mid-Day Market Update: Snap Surges After Strong Q4 Results; Arlo Technologies Shares Slide

Financial news for MGNX dated on 2019-02-06: H.C. Wainwright Raises MacroGenics Price Target From \$34 To \$39 Reiterates Buy As Firm Notes 'With a PFS win and OS trending positive, we anticipate BLA approval during 2H20'

Financial news for MGNX dated on 2019-02-06: Mid-Morning Market Update: Markets Open Lower; General Motors Earnings Beat Estimates

Financial news for MGNX dated on 2019-02-06: MacroGenics shares are trading higher after the company announced positive results from its phase 3 SOPHIA study of margetuximab.

Financial news for MGNX dated on 2019-02-06: 33 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MGNX dated on 2019-02-06: A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings

Financial news for MGNX dated on 2019-02-06: MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

Financial news for MGNX dated on 2019-02-04: Mid-Morning Market Update: Markets Mixed; Clorox Profit Tops Expectations

Financial news for MGNX dated on 2019-02-04: 7 Biggest Price Target Changes For Monday

Financial news for MGNX dated on 2019-02-04: MacroGenics shares are trading lower after Citigroup downgraded the stock from Neutral to Sell and lowered the price target from \$22 to \$10.

Financial news for MGNX dated on 2019-02-04: Benzinga's Top Upgrades, Downgrades For February 4, 2019

Financial news for MGNX dated on 2019-02-04: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for MGNX dated on 2019-02-04: Citigroup Downgrades MacroGenics to Sell, Lowers Price Target to \$10

Financial news for MGNX dated on 2019-01-31: MacroGenics Option Alert: Feb 15 \$15 Calls at the Ask: 500 @ \$0.95 vs 19 OI; Earnings 2/26 After Close [est] Ref=\$11.7

Financial news for MGNX dated on 2019-01-25: MacroGenix shares are trading higher after the FDA lifted its partial clinical hold on the company's MGD009 program.

Financial news for MGNX dated on 2019-01-25: MacroGenics Announces Removal Of Partial Clinical Hold On MGD009 Program By FDA

Financial news for MGNX dated on 2019-01-24: Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019

Financial news for MGNX dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for MGNX dated on 2018-12-11: 46 Biggest Movers From Yesterday

Financial news for MGNX dated on 2018-12-10: Mid-Afternoon Market Update: Crude Oil Down 2%; Veritone Shares Jump

Financial news for MGNX dated on 2018-12-10: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for MGNX dated on 2018-12-10: Mid-Day Market Update: Down Down 350 Points; Xperi Shares Spike Higher

Financial news for MGNX dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for MGNX dated on 2018-12-10: Mid-Morning Market Update: Markets Open Lower; Tivity Health To Acquire Nutrisystem

Financial news for MGNX dated on 2018-12-10: MacroGenics shares are trading lower after the company late Friday reported a clinical hold on its Phase 1 study of MGD009 due to adverse events in the trial.

Financial news for MGNX dated on 2018-12-10: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for MGNX dated on 2018-12-10: 6 Stocks To Watch For December 10, 2018

Financial news for MGNX dated on 2018-12-07: MacroGenics Shares To Resume Trade At 4:30 p.m. EST

Financial news for MGNX dated on 2018-12-07: UPDATE: MacroGenics Initiated Partial Clinical Hold On MGD009 Phase 1 Studies Following Hepatic Adverse Events In MGD009 Trial

Financial news for MGNX dated on 2018-12-07: MacroGenics Announces Partial Clinical Hold On MGD009 Phase 1 Studies

Financial news for MGNX dated on 2018-12-07: MacroGenics Shares Halted News Pending

Financial news for MGNX dated on 2018-12-06: Trianni, Inc. and MacroGenics, Inc. Announce License Agreement For Trianni Mouse; Financial Terms Not Disclosed

Financial news for MGNX dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for MGNX dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for MGNX dated on 2018-11-29: UPDATE: MacroGenics To Receive \$25M Upfront Cash Payment, Potential Future Milestones, Royalties Up To \$140M

Financial news for MGNX dated on 2018-11-29: MacroGenics Reports Exclusive Collaboration, License Deal With Zai Lab For Development, Commercialization Of Margetuximab, MGD013, TRIDENT Molecule In Greater China

Financial news for MGNX dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for MGNX dated on 2018-11-07: MacroGenics Q3 EPS \$(0.81) Beats \$(1.32) Estimate, Sales \$20.798M Beat \$5.04M Estimate

Financial news for MGNX dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for MGNX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for MGNX dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for MGNX dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for MGNX dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for MGNX dated on 2018-10-29: NanoString Technologies and MacroGenics Announce a Research Agreement to Identify Biomarkers for MacroGenic's MGD013

Financial news for MGNX dated on 2018-09-10: BTIG Research Assumes MacroGenics at Buy, Announces Price Target \$30

Financial news for MGNX dated on 2018-08-07: MacroGenics Q2 EPS \$(1.03) Beats \$(1.22) Estimate, Sales \$18.83M May Not Compare To \$4.21M Estimate

Financial news for MGNX dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmmed's Antibiotic Faces FDA Panel

Financial news for MGNX dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for MGNX dated on 2018-05-31: Evercore ISI Group Initiates Coverage On MacroGenics with Outperform Rating, Announces \$33 Price Target

Financial news for MGNX dated on 2018-05-09: 53 Biggest Movers From Yesterday

Financial news for MGNX dated on 2018-05-08: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MGNX dated on 2018-05-07: MacroGenics Q1 EPS \$(1.34) Misses \$(1.08) Estimate, Sales \$4.695M Miss \$6.79M Estimate

Financial news for MGNX dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for MGNX dated on 2018-03-28: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MGNX dated on 2018-03-28: MacroGenics Prices 4.5M Share Offering At \$21.25/Share

Financial news for MGNX dated on 2018-03-28: 38 Biggest Movers From Yesterday

Financial news for MGNX dated on 2018-03-27: MacroGenics Shares Down 12.4% After Co. Monday Announced 4.5M Share Common Stock Offering

Financial news for MGNX dated on 2018-03-27: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MGNX dated on 2018-03-26: MacroGenics Reports Offering Of 4.5M Shares Of Common Stock

Financial news for MGNX dated on 2018-03-06: 32 Biggest Movers From Yesterday

Financial news for MGNX dated on 2018-03-05: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for MGNX dated on 2018-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2018

Financial news for MGNX dated on 2018-03-05: H.C. Wainwright Initiates Coverage On MacroGenics with Buy Rating, Announces \$38.00 Price Target

Financial news for MGNX dated on 2018-02-27: MacroGenics Reports FY17 Net Loss \$19.6M vs \$58.5M In FY16, Sales \$157.7M vs \$91.9M Last Year

Financial news for MGNX dated on 2018-01-25: 42 Biggest Movers From Yesterday

Financial news for MGNX dated on 2018-01-24: MacroGenix Shares Up 16.59% After Tuesday Reporting Continuation Of SOPHIA Study Of Margetuximab

Financial news for MGNX dated on 2018-01-23: MacroGenics Reports Continuation Of SOPHIA Study Of Margetuximab Based On Completion Of Interim Futility Analysis

Financial news for MGNX dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for MGNX dated on 2018-01-05: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for MGNX dated on 2018-01-04: MacroGenics Reports Research Collaboration Deal With Roche For Development Of Novel Bispecific Molecule

Financial news for MGNX dated on 2017-11-08: MacroGenics Reports Q3 EPS \$(1.28) vs \$(1.09) Est., Sales \$1.663M vs \$4.11M Est.

Financial news for MGNX dated on 2017-10-26: 36 Biggest Movers From Yesterday

Financial news for MGNX dated on 2017-10-25: Mid-Afternoon Market Update: Acadia Healthcare Tumbles After Downbeat Results; MacroGenics Shares Surge

Financial news for MGNX dated on 2017-10-25: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MGNX dated on 2017-10-25: Mid-Day Market Update: Dow Falls Over 100 Points; Chipotle Shares Drop On Earnings Miss

Financial news for MGNX dated on 2017-10-25: Incyte and MacroGenics Announce Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012

Financial news for MGNX dated on 2017-09-10: MacroGenics Presents Phase 1 Data for Flotetuzumab, CD123 x CD3 DART Molecule at ESMO 2017

Financial news for MGNX dated on 2017-09-05: MacroGenics Reports the NIAID To Exercise First Of 2 Options Under HIV Contract, Funding MDG014 Into Phase 1 Trials

Financial news for MGNX dated on 2017-09-05: MacroGenics Reports First Pateint Dosed With MGD013, Submission of IND With The FDA For MGD014

Financial news for MGNX dated on 2017-09-01: 12 Biggest Mid-Day Losers For Friday

Financial news for MGNX dated on 2017-09-01: Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge

Financial news for MGNX dated on 2017-09-01: Mid-Morning Market Update: Markets Mostly Higher; Lululemon Beats Q2 Estimates

Financial news for MGNX dated on 2017-08-31: MacroGenics Reports Termination Of Duvortuxizumab Collab., License Deal With J&J's Janssen

Financial news for MGNX dated on 2017-08-02: MacroGenics Reports Q2 EPS \$(1.14) vs \$(0.83) Est., Sales \$1.666M vs \$12.44M Est.

Financial news for MGNX dated on 2017-06-17: MacroGenics Reports Single Dose Administration of MGD010 Delivers Immunomodulatory Effect that Counters B-cell Function #EULAR2017

Financial news for MGNX dated on 2017-05-03: MacroGenics Reports Q1 EPS \$(1.08) vs \$(0.97) Est., Sales \$2.055M May Not Compare To \$5.56M Est.

Financial news for MGNX dated on 2017-04-27: MacroGenics Reports Offering of 1.1M Shares at \$21.50/Share

Financial news for MGNX dated on 2017-03-31: Raymond James Initiates Coverage On MacroGenics With Outperform, Announces \$26 Price Target

Financial news for MGNX dated on 2017-03-02: Nomura Initiates Coverage On MacroGenics at Buy

Financial news for MGNX dated on 2017-02-28: MacroGenics Reports FY16 EPS \$(1.69) vs \$(1.61) Est., Sales \$91.88M vs \$97.42M Est.

Financial news for MGNX dated on 2017-01-05: MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA

Financial news for MGNX dated on 2016-12-29: BB Biotech AG Reports 5.2% Stake In MacroGenics

Financial news for MGNX dated on 2016-12-19: SunTrust Robinson Humphrey Initiates Coverage On MacroGenics at Buy, Announces \$30.00 Target

Financial news for MGNX dated on 2016-12-12: MacroGenics Licenses Synthon's Technology to Develop an Anti-B7-H3 ADC, Terms Not Disclosed

Financial news for MGNX dated on 2016-11-02: MacroGenics Reports Q3 EPS \$(0.97) vs. Est. \$(0.80), Rev. \$3.255M vs. Est. \$12.45M

Financial news for MGNX dated on 2016-10-20: Can You Guess This Chart?

Financial news for MGNX dated on 2016-09-20: MacroGenics Names Dr. Ezio Bonvini Chief Scientific Officer, Eric Rissier Chief Business Officer

Financial news for MGNX dated on 2016-09-12: Takeda and MacroGenics Reports the Conclusion of their MGD010 License and Option Agreement

Financial news for MGNX dated on 2016-09-12: MacroGenetics MGD010 License and Option Agreement Ends, Regains Worldwide Rights

Financial news for MGNX dated on 2016-09-07: Cowen & Company Initiates Coverage on MacroGenics at Outperform

Financial news for MGNX dated on 2016-08-04: Citigroup Downgrades MacroGenics to Neutral, Raises PT to \$32.00

Financial news for MGNX dated on 2016-08-03: MacroGenics Reports Q2 EPS \$1.12, Rev. \$80.67M

Financial news for MGNX dated on 2016-06-28: MacroGenics Announces Licensing Contract With Janssen, Will Get \$75M Upfront Payment

Financial news for MGNX dated on 2016-06-10: MacroGenics Reports Data from Phase 1 Study of MGD010 at EULAR: Well Tolerated at All Dose Levels with No Serious Adverse Effects

Financial news for MGNX dated on 2016-05-18: Midday Gainers In Depth

Financial news for MGNX dated on 2016-05-18: 10 Stocks Gaining In Wednesday's Pre-Market: Heavy M&A Activity

Financial news for MGNX dated on 2016-05-18: MacroGenics Enters Collaboration and License Agreement with Janssen for Treatment of Cancer

Financial news for MGNX dated on 2016-05-10: First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics Of \$2M

Financial news for MGNX dated on 2016-05-04: MacroGenics Reports Q1 EPS \$(0.88) vs. Est. \$(0.67)

Financial news for MGNX dated on 2016-04-07: BTIG Starts MacroGenics At Buy, Sees 63% Upside

Financial news for MGNX dated on 2016-04-07: BTIG Research Initiates Coverage on MacroGenics at Buy, Announces \$35.00 PT

Financial news for MGNX dated on 2016-03-16: MacroGenetics To Present 5 Posters At AACR Meeting, 4 Of 5 Posters Refer To Programs Based On MacroGenetics Dual-Affinity Re-Targeting Bispecific Technology

Financial news for MGNX dated on 2016-03-04: Director Costa Buys 10,000 Shares of MacroGenics @\$17.20/Share -Form 4

Financial news for MGNX dated on 2016-02-25: Benzinga's Top Initiations

Financial news for MGNX dated on 2016-02-25: Morgan Stanley Initiates Coverage on MacroGenics at Equal-weight, Announces \$20.00 PT

Financial news for MGNX dated on 2016-02-18: Benzinga's Top Initiations

Financial news for MGNX dated on 2016-02-18: Janney Capital Initiates Coverage on MacroGenics at Buy, Announces \$36.00 PT

Financial news for MGNX dated on 2015-11-07: Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab Presented at 30th Annual SITC Meeting 2015

Financial news for MGNX dated on 2015-11-05: Publication in PLOS Pathogens Shows the Potential of DART(r) Molecules for HIV Reservoir Elimination Strategy

Financial news for MGNX dated on 2015-11-04: MacroGenics Reports Q3 EPS \$(0.46) May Not Compare \$(0.26) Est., Sales \$14.7M May Not Compare \$27M Est.

Financial news for MGNX dated on 2015-10-28: MacroGenics Regains European, Other Regional Rights to Enoblituzumab

Financial news for MGNX dated on 2015-09-17: 8-K from MacroGenics Shows Co. Entered Deal with Natinoal Institute of Allergy, Infectious Diseases for Product Development, Advancement of DART-1, DART-2

Financial news for MGNX dated on 2015-09-17: Benzinga's Top Initiations

Financial news for MGNX dated on 2015-09-17: Citigroup Initiates Coverage on MacroGenics at Neutral, Announces \$31.00 PT

Financial news for MGNX dated on 2015-08-25: Market Panic Has Created 'Compelling' Opportunities In Biotech

Financial news for MGNX dated on 2015-08-25: Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cemptra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics

Financial news for MGNX dated on 2015-07-28: MGD011 Moves Into Clinical Development, Triggers \$10M Milestone Payment

Financial news for MGNX dated on 2015-07-15: US Stock Futures Edge Higher; Bank of America Earnings In Focus

Financial news for MGNX dated on 2015-07-15: MacroGenics Prices 3.525M Share Offering @\$37.00/Share

Financial news for MGNX dated on 2015-07-13: MacroGenics Reportys Offering OF 3.25M Shares

Financial news for MGNX dated on 2015-05-30: MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO

Financial news for MGNX dated on 2015-04-21: Biotech Investors: May 29th Could Be A Big Day

Financial news for MGNX dated on 2015-03-16: MacroGenics To Receive \$3M Milestone Payment From Topeka, Initiates Phase 1 Study Of MGD010

Financial news for MGNX dated on 2015-03-16: MacroGenics Initiates Phase 1 Study Of MGD010 For Autoimmune Disorder Treatment

Financial news for MGNX dated on 2014-12-22: MacroGenics Enters Collaboration, License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies, MacroGenics to Receive \$50M Upfront License Fee, \$75M Equity Investment by JNJ

Financial news for MGNX dated on 2014-12-18: Benzinga's Volume Movers

Financial news for MGNX dated on 2014-12-15: Roth Capital Adding MacroGenics To "Focus List", Maintains Buy Rating With A PT Of \$45

Financial news for MGNX dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for MGNX dated on 2014-11-12: UPDATE: Stifel Reiterates On MacroGenics On Strategic Development Shift

Financial news for MGNX dated on 2014-11-12: Stifel Nicolaus Maintains Buy on MacroGenics, Lowers PT to \$51.00

Financial news for MGNX dated on 2014-11-12: MacroGenics Files Up to \$150M Mixed Securities Shelf

Financial news for MGNX dated on 2014-11-11: MacroGenics Reports Q3 EPS Loss Of \$0.14, Sales \$18.4M

Financial news for MGNX dated on 2014-08-05: MacroGenics Reports Q2 EPS Loss \$0.44 vs Est. Loss \$0.26

Financial news for MGNX dated on 2014-07-11: Oppenheimer Initiates Coverage on MacroGenics at Outperform, Announces \$48.00 PT

Financial news for MGNX dated on 2014-07-10: Oppenheimer Initiates Coverage on MacroGenics at Outperform, Announces \$48.00 PT

Financial news for MGNX dated on 2014-06-19: MacroGenics Initiates Phase 1 MGD006 Study

Financial news for MGNX dated on 2014-06-17: CMC Biologics Announces Agreement For Clinical Manufacturing With MacroGenics

Financial news for MGNX dated on 2014-06-09: Top Healthcare Movers For June 9, 2014

Financial news for MGNX dated on 2014-06-09: MacroGenics Shares Up 9+%, Roth Capital Initiated New Buy Rating, \$28 Target

Financial news for MGNX dated on 2014-05-27: MacroGenics To Get \$15M Upfront For DART Development

Financial news for MGNX dated on 2014-05-06: CMC Biologics, MacroGenics Announce Process Development and Manufacturing Agreement for Oncology Product Candidate

Financial news for MGNX dated on 2014-04-28: MacroGenics to Present Pre-Clinical Data on MGD010 at IMMUNOLOGY 2014

Financial news for MGNX dated on 2014-04-09: 13G Filing from Point72 Asset Mgmt on MacroGenics Shows 6.6% Stake

Financial news for MGNX dated on 2014-04-07: MacroGenics Presents Positive Pre-Clinical Data for MGD007 Against Colorectal Cancer Cells at AACR 2014

Financial news for MGNX dated on 2014-03-31: MacroGenics to Present Pre-clinical Data on MGD007 at AACR Annual Meeting

Financial news for MGNX dated on 2014-03-21: Stifel Nicolaus Maintains Buy on MacroGenics, Raises PT to \$53.00

Financial news for MGNX dated on 2014-03-06: MacroGenics Appoints Matthew Fust to Its Board of Directors

Financial news for MGNX dated on 2014-03-05: Stifel Nicolaus Maintains Buy on MacroGenics, Raises PT to \$51.00

Financial news for MGNX dated on 2014-02-18: UPDATE: Bank of America Upgrades MacroGenics on Broad Immunotherapy Pipeline

Financial news for MGNX dated on 2014-02-18: Bank of America Upgrades MacroGenics to Buy, Raises PT to \$50.00

Financial news for MGNX dated on 2014-02-12: MacroGenics Prices 3M Share Offering at \$36.50/Share

Financial news for MGNX dated on 2014-02-10: MacroGenics Announces 2.5M Share Offering

Financial news for MGNX dated on 2014-02-10: MacroGenics Announces Proposed 2.5M Share Public Offering of Common Stock

Financial news for MGNX dated on 2013-12-11: MacroGenics Announces Publication of Cancer Stem Cell Research in Lung Cancer in PLOS ONE

Financial news for MGNX dated on 2013-12-04: UPDATE: Wedbush Initiates Coverage On MacroGenics On Prospects Of Cancer Treatment Drugs

Financial news for MGNX dated on 2013-12-04: Benzinga's Top Initiations

Financial news for MGNX dated on 2013-12-04: Wedbush Initiates Coverage on MacroGenics at Outperform, Announces \$70.00 PT

Financial news for MGNX dated on 2013-12-03: Wedbush Initiates Coverage on MacroGenics at Outperform, Announces \$70.00 PT

Financial news for MGNX dated on 2013-11-04: UPDATE: Bank of America Initiates Coverage on MacroGenics on Multiple Immunotherapy Platforms

Financial news for MGNX dated on 2013-11-04: Stifel Nicolaus Initiates Coverage on MacroGenics at Buy, Announces \$35.00 PT

Financial news for MGNX dated on 2013-11-04: Benzinga's Top Initiations

Financial news for MGNX dated on 2013-11-04: Leerink Swann Initiates Coverage on MacroGenics at Outperform, Announces \$34.00 PT

Financial news for MGNX dated on 2013-11-04: Bank of America Initiates Coverage on MacroGenics at Neutral, Announces \$30.00 PO

Financial news for MGNX dated on 2013-10-10: MacroGenics Shares Open for Trade at \$24 After Pricing at \$16/Share

Financial news for MGNX dated on 2013-10-01: MacroGenics to Offer 4M Shares in \$14-16/Share Range

Financial news for MGNX dated on 2013-09-04: MacroGenics Files \$60M IPO, Will List on NASDAQ